Viewing Study NCT01718158


Ignite Creation Date: 2025-12-25 @ 12:16 AM
Ignite Modification Date: 2025-12-31 @ 4:17 AM
Study NCT ID: NCT01718158
Status: COMPLETED
Last Update Posted: 2015-10-09
First Post: 2012-10-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
Sponsor: Bristol-Myers Squibb
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module